ADMSのチャート
ADMSの企業情報
| symbol | ADMS |
|---|---|
| 会社名 | Adamas Pharmaceuticals Inc （アダマス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アダマス・ファーマシューティカル（Adamas Pharmaceuticals Inc）は製薬会社である。同社は慢性神経障害の罹患者の日常生活を管理するための医薬品の開発に従事する。同社は耐性の問題なしで救済を達成するために、疾患活動および薬物応答の時間依存性生物学的影響の理解に基づくプラットフォームを提供する。同社は慢性神経障害に対処するためのクロノ同期療法のポートフォリオを開発した。最初の製品候補は、パーキンソン病（PD）患者のレボドパ誘発ジスキネジー（LID）の治療のための、クロモ同期型アマンタジン療法であるADS-5102である。これらの患者におけるADS-5102の第Ⅱ相実証試験を完了した。同社の第III相臨床プログラムには、EASED、EASE LIDおよびEASE LID 3の3つのプラセボ対照試験が含まれる。同社の2番目の製品候補は、てんかん（部分発作）の治療用単剤化合物の延長放出型であるADS-4101である。 アダマス・ファ―マシュ―ティカルズは米国の特殊製薬会社。アルツハイマ―病、パ―キンソン病、TBI(全身被ばく)、てんかん、精神病、うつ病などの中枢神経系の慢性疾患、及び被ばく者のための治療法の開発、商業化に従事。承認薬の薬物動態プロファイルを強化することで、一人で使用できる多剤混合薬の新規治療薬を作ることを実現。本社はカリフォルニア州。 Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. |
| 本社所在地 | 1900 Powell Street Suite 750 Emeryville CA 94608 USA |
| 代表者氏名 | Gregory T. Went グレゴリーT.ウェント |
| 代表者役職名 | Chairman of the Board Chief Executive Officer Co-Founder |
| 電話番号 | +1 510-450-3554 |
| 設立年月日 | 36831 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 147人 |
| url | www.adamaspharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/adms |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -111.08500 |
| 終値（lastsale） | 17.44 |
| 時価総額（marketcap） | 474201500.32 |
| 時価総額 | 時価総額（百万ドル） 475.56100 |
| 売上高 | 売上高（百万ドル） 10.68700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 383.86000 |
| 当期純利益 | 当期純利益（百万ドル） -121.68100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Adamas Pharmaceuticals Inc revenues increased from $2K to $10.1M. Net loss increased 88% to $69M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other General and Administrative. increase from $17.3M to $47.7M (expense) Interest expense increase from $729K to $9.9M (expense). |
ADMSのテクニカル分析
ADMSのニュース
Squarepoint Ops LLC Sells 39,923 Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) 2021/11/27 10:08:47 Transcript Daily
Squarepoint Ops LLC decreased its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 69.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 17,561 shares of the specialty pharmaceutical companys stock after selling 39,923 shares during the quarter. Squarepoint Ops LLCs holdings in Adamas Pharmaceuticals were worth $93,000 at the end of the most []
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer 2021/11/23 13:00:00 Intrado Digital Media
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.
New Zealands Counties Energy Partners with GE Digital for its Digital Utility Transformation 2021/11/22 15:00:00 Kwhen Finance
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Short Interest Down 44.9% in October 2021/11/19 10:18:42 Transcript Daily
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was the target of a significant drop in short interest in October. As of October 29th, there was short interest totalling 881,300 shares, a drop of 44.9% from the October 14th total of 1,600,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 0.8 days. []
Adamas Pharmaceuticals (NASDAQ:ADMS) Lowered to Market Perform at Northland Securities 2021/11/17 12:36:41 Transcript Daily
Northland Securities lowered shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from an outperform rating to a market perform rating in a research report released on Wednesday, The Fly reports. ADMS has been the topic of several other research reports. Piper Sandler lowered Adamas Pharmaceuticals from an overweight rating to a neutral rating and boosted their price target []
Squarepoint Ops LLC Sells 39,923 Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) 2021/11/27 10:08:47 Transcript Daily
Squarepoint Ops LLC decreased its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 69.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 17,561 shares of the specialty pharmaceutical companys stock after selling 39,923 shares during the quarter. Squarepoint Ops LLCs holdings in Adamas Pharmaceuticals were worth $93,000 at the end of the most []
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer 2021/11/23 13:00:00 Intrado Digital Media
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.
New Zealands Counties Energy Partners with GE Digital for its Digital Utility Transformation 2021/11/22 15:00:00 Kwhen Finance
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Short Interest Down 44.9% in October 2021/11/19 10:18:42 Transcript Daily
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was the target of a significant drop in short interest in October. As of October 29th, there was short interest totalling 881,300 shares, a drop of 44.9% from the October 14th total of 1,600,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 0.8 days. []
Adamas Pharmaceuticals (NASDAQ:ADMS) Lowered to Market Perform at Northland Securities 2021/11/17 12:36:41 Transcript Daily
Northland Securities lowered shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from an outperform rating to a market perform rating in a research report released on Wednesday, The Fly reports. ADMS has been the topic of several other research reports. Piper Sandler lowered Adamas Pharmaceuticals from an overweight rating to a neutral rating and boosted their price target []